A half-life is a population-level description of concentration change under defined conditions. It is not a countdown to the end of a symptom. This difference becomes important when someone feels unwell after a long-acting preparation and asks how long they should expect to wait.
The controlled healthy-adult CJC study reported prolonged exposure and evidence of accumulation with repeated administration. It did not establish a timetable for resolving an individual's fatigue, swelling or other complaint after an unverified product or combination.
Several timelines may overlap
The measured compound, a downstream hormone response and a clinical symptom can have different trajectories. A symptom may also have a cause unrelated to the proposed active ingredient. Knowing one pharmacokinetic parameter cannot identify that cause.
Repeated exposure complicates the picture further. An interval since the most recent exposure does not necessarily describe the total exposure history. Nor does a published average show how a particular person's physiology, formulation or other medicines affect the response.
It is therefore inappropriate to use a half-life calculation to reassure someone that a significant symptom will resolve by a particular date. The opposite claim, that a symptom must persist for the full reported half-life, is equally unsupported. Clinical assessment depends on the symptom and context, not just a number.
A useful account for a clinician includes the exact product label, other substances, exposure dates and the development of symptoms. That is different from experimenting with another peptide to counteract the problem. Adding substances can make attribution and assessment more difficult.
The evidence supports describing DAC CJC as a long-acting research construct. It does not supply a safe waiting period, a reversal strategy or a switching schedule. Severe or concerning symptoms warrant medical assessment rather than reassurance from an online decay chart. The uncertainty does not support instructions for managing an experimental exposure at home.